Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

Research and Innovation Action · Running

IntReALL 2020 International Study for Treatment of Childhood Relapsed ALL 2020

Coordinator
Charite - Universitaetsmedizin Berlin, Germany
Runs
1 May 2023 to 30 April 2028
Status
Running
EU funding
€6.1m
Total cost
€6.1m
Partners
26 organisations in 20 countries
Type
Research and Innovation Action
Grant agreement
101104582

What the project is doing

In the project's own words, from its summary on CORDIS.

Relapse of acute lymphoblastic leukemia (ALL) remains a leading cause of mortality in childhood cancer. IntReALL 2020 will conduct randomized and historically controlled trials in children with relapsed B-cell precursor (BCP) ALL with the aim to replace toxic chemotherapy with better tolerated and more efficacious immunotherapeutic drugs. In standard risk (SR) patients, the CD22 directed antibody-drug conjugate inotuzumab ozogamicin (InO) will be randomly compared with standard of care (SOC) ALL-R3 induction.

All patients will receive one SOC consolidation- and one Blina course, compared to historical controls. SR patients with MRD good response will receive 2 additional Blina courses replacing chemotherapy randomly compared with SOC. Patients with high-risk relapse will receive induction investigating InO versus ALL-R3 in an industry-sponsored trial, followed by IntReALL consolidation and allogeneic HSCT. Patients with isolated extramedullary (IEM) relapse are treated based on ALL-REZ BFM 2002 backbone.

IntReALL 2020 will establish a federated relapsed/refractory leukaemia board generating personalized recommendations based on clinical, molecular-genetic and drug response profiling data. Patients with very-high risk disease will receive experimental/personalized therapies, including a trial investigating CD19-directed chimeric receptor antigen (CAR) T-cells produced in academic institutions. Other CAR T-cells trials as well as an induction trial for T-ALL relapse will be developed.

Documentation and monitoring of the trials and the individualized treatment will be realized using the MARVIN database. Comprehensive statistical and data management activities will warrant the accuracy and interpretability of the data. IntReALL 2020 involves representatives from participating pharmaceutical companies and EMA as well as patient/parent advocates to discuss strategies for developing new drugs within academic trials warranting a benefit for all patients on the results.“This action is part of the Cancer Mission cluster of projects on ‘Diagnosis and treatment’.”

Topics

Who is involved

OrganisationCityCountryRole
Charite - Universitaetsmedizin BerlinBerlinGermanyCoordinator
St. Anna Kinderkrebsforschung GmbHWienAustriaParticipant
Universiteit GentGentBelgiumParticipant
Universitat ZurichZurichSwitzerlandAssociatedpartner
Fakultni Nemocnice Motol a HomolkaPraha 5CzechiaParticipant
Gpoh Zdm GgmbhHannoverGermanyParticipant
Medizinische Hochschule HannoverHannoverGermanyParticipant
Tp21 GmbHBerlinGermanyParticipant
Region HovedstadenHillerodDenmarkParticipant
Geniko Nosokomeio Paidon Athinon I Agia SofiaAthinaGreeceParticipant
Fundacion Para La Formacion E Investigacion Sanitarias De La Region De MurciaMurciaSpainParticipant
Servicio Murciano De SaludMurciaSpainThird party
Hus-YhtymaHelsinkiFinlandParticipant
Assistance Publique Hopitaux De ParisParisFranceParticipant
Centre Hospitalier Universitaire De NiceNiceFranceParticipant
Imagine for Margo Children Without CancerSaint-Germain-En-LayeFranceParticipant
Magyar Gyermekonkologiai Halozat -Magyar Gyermekonkologusok Es Gyermekhematologusok TarsasagaBudapestHungaryParticipant
The Foundation for Medical Research Infrastructural Development and Health Services Next to the Medical Center Tel AvivTel AvivIsraelParticipant
Ospedale Pediatrico Bambino GesuRomaItalyParticipant
Prinses Maxima Centrum Voor Kinderoncologie BVUtrechtNetherlandsParticipant
Oslo Universitetssykehus HfOsloNorwayParticipant
Uniwersytet Medyczny Im Piastow Slaskich We WroclawiuWroclawPolandParticipant
Instituto Portugues De Oncologia De Lisboa Francisco Gentil EpeLisboaPortugalParticipant
Institutul Clinic FundeniBucurestiRomaniaParticipant
Region StockholmStockholmSwedenParticipant
Univerzitetni Klinicni Center LjubljanaLjubljanaSloveniaParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI